Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Sanofi save search
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MLTX | $42.31 -2.76% -2.84% 230K
|
|
| O: 0.51%
H: 0.86%
C: -4.53%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
nanobody meeting trial
Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -0.43%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.59%
H: 2.06%
C: 2.06%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.28%
H: 0.75%
C: 0.4%
review cancer trials global trial
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 3.26%
H: 2.37%
C: -1.53%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals trial
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
ibi311 disease thyroid eye trial
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
collaboration trial sanofi
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
Published: 2024-01-24 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.01%
H: 0.69%
C: -0.75%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
antibody start cancer treatment pharmaceuticals trial
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
Published: 2023-12-21 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
lung axes cancer trial sanofi
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Published: 2023-12-21 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
program trial sanofi
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
trial potential
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: -0.41%
H: 8.09%
C: 7.64%
kt-474 first dermatitis payment trial therapeutics sanofi
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Published: 2023-12-07 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
sarclisa free trial
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
Published: 2023-11-13 (Crawled : 17:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 0.14%
H: 3.3%
C: 3.03%
kt-474 publication trial therapeutics results
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
Published: 2023-10-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -5.43%
kt-474 trial therapeutics phase 2
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -5.43%
kt-474 payment trial therapeutics sanofi
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.